MARKET

GLPG

GLPG

Galapagos Nv
NASDAQ
44.22
-1.00
-2.21%
After Hours: 44.22 0 0.00% 16:01 10/05 EDT
OPEN
44.11
PREV CLOSE
45.22
HIGH
44.38
LOW
43.50
VOLUME
58.74K
TURNOVER
0
52 WEEK HIGH
72.11
52 WEEK LOW
41.65
MARKET CAP
2.91B
P/E (TTM)
-47.0526
1D
5D
1M
3M
1Y
5Y
EMA panel approves amending label for Galapagos' Jyseleca on testicular function effects
Belgian pharmaceutical firm Galapagos (NASDAQ:GLPG) on Monday said t...
Seekingalpha · 2d ago
BRIEF-Galapagos Receives Positive CHMP Opinion For Jyseleca European Label Update
BRIEF-Galapagos Receives Positive CHMP Opinion For Jyseleca European Label Update
Reuters · 2d ago
Galapagos Receives Committee For Medicinal Products For Human Use Opinion For Jyseleca European Label Update Based On Testicular Function Safety Data From MANTA/RAy Studies
Type II variation1 regulatory application to amend the European label of Jyseleca® (filgotinib) based on data from MANTA and MANTA-RAy studies in patients with inflammatory bowel disease (IBD) and rheumatic
Benzinga · 2d ago
Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies
Type II variation1 regulatory application to amend the European label of Jyseleca® (filgotinib) based on data from MANTA and MANTA-RAy studies in patients with inflammatory bowel disease (IBD) and rheumatic conditions (RC) respectively Mechelen, Belgium; 3...
GlobeNewswire · 2d ago
BRIEF-Galapagos Increases Share Capital Through Subscription Right Exercises
BRIEF-Galapagos Increases Share Capital Through Subscription Right Exercises
Reuters · 09/28 08:05
ASTS, ONTX and BITF among pre market gainers
Ventyx Biosciences (VTYX) +57%. Regulus Therapeutics (<a href=...
Seekingalpha · 09/12 12:40
Where Galapagos Stands With Analysts
Analysts have provided the following ratings for Galapagos (NASDAQ:GLPG) within the last quarter:
Benzinga · 09/09 13:28
Galapagos cut at Morgan Stanley on positive but slow transformation
Galapagos (NASDAQ:GLPG) was downgraded by Morgan Stanley to Equal Weight f...
Seekingalpha · 09/09 12:32
More
About GLPG
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve quality of life of patients across the globe. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.

Webull offers kinds of Galapagos NV stock information, including NASDAQ:GLPG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GLPG stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading GLPG stock methods without spending real money on the virtual paper trading platform.